Novartis to review $600m global media business

Be the first to comment
Novartis: calls global media review
Novartis: calls global media review

Novartis, the pharmaceutical giant, is gearing up to launch a review of its estimated $600m global media business.

WPP's MEC is the incumbent on the global business, including in the UK.

In 2008 Novartis consolidated its US media planning and buying into MEC after moving its business from sibling agency Mindshare in a global realignment.

The company, which has a consumer health business that markets over the counter medicines such as Tixylix and Savlon, spent £9m in the UK in the past 12 months, according to Nielsen.

Novartis, which is headquartered in Basel, Switzerland, has three other businesses called Pharmaceuticals, Vaccines and Diagnostics, and Sandoz Generics, a global supplier of generic medicines that are produced after a popular medicine's patent has expired.

SUBSCRIBE TO CAMPAIGN

Only £49 for 3 months

Includes every print & iPad edition, plus full access to Campaign online and other Brand Republic sites

SUBSCRIBE

Campaign Jobs

Thousands of jobs across advertising, creative, marketing and media

Trending

Just published